Table 5.
Rate of Change in Lung Function Parameters Values (ml/Year for Predicted Values) Between Inhaled Pharmacotherapy Use (Note Pharmacotherapy Level Adjudged from What Was Reported at the Final Lung Function Test)
| Univariate | No Medication (n=25) | SA/LA BA/MA (n=25) | SA/LA BA/MA + ICS (n=63) | p-value |
|---|---|---|---|---|
| Forced vital capacity (FVC) | ||||
| Pre-BD (L) | −22.5 (−79.73, 207.02) | 17.77 (−91.48, 113.8) | −52.66 (−197.52, 60.36) | 0.074 |
| Pre-BD (%) | −0.82 (−5.19, 4.55) | 2.7 (−3.57, 7.76) | −0.6 (−4.37, 2.01) | 0.164 |
| Post-BD (L) | 32.68 (−64.91, 112.05) | 10.57 (−77.6, 80.38) | −50.47 (−141.14, 64.71) | 0.064 |
| Post-BD (%) | 0.72 (−4.2, 4.17) | 2.79 (−1.01, 6.04) | 0 (−3.52, 2.43) | 0.199 |
| Forced expiratory volume in one second (FEV1) | ||||
| Pre-BD (L) | −5.76 (−63.19, 67.34) | 15.46 (−73.5, 74.62) | −48.64 (−110.18, 62.5) | 0.022* |
| Pre-BD (%) | −0.69 (−6.09, 4.17) | 2 (−2.27, 4.4) | −0.82 (−3.4, 1.89) | 0.027* |
| Post-BD (L) | −27.53 (−116.19, 142.87) | 21.59 (−45.02, 56.66) | −37.95 (−123.65, 60.17) | 0.593 |
| Post-BD (%) | −0.69 (−4.35, 5.98) | 2.65 (−2, 4.61) | −0.81 (−4.4, 2.13) | 0.135 |
| Excessive FEV1 (pre-BD) decline^ | 13 (52) | 11 (44) | 40 (64) | 0.218 |
| FEV1/FVC | ||||
| Pre-BD (AV) | 0 (−0.03, 0.01) | 0 (−0.02, 0.01) | 0 (−0.04, 0.01) | 0.880 |
| Pre-BD (%) | 0 (−2.76, 1.82) | −0.66 (−3.03, 2.02) | 0 (−4.85, 1.83) | 0.826 |
| Post-BD (AV) | −0.01 (−0.03, 0) | 0 (−0.02, 0) | −0.01 (−0.03, 0.02) | 0.645 |
| Post-BD (%) | −0.35 (−2.73, 3.49) | −0.53 (−3, 0.98) | 0 (−4.82, 1.81) | 0.988 |
Notes: Data were median (IQR). P-values were obtained via univariate quantile regression for continuous parameters and chi-squared test for categorical parameters. ^(Baseline predicted FEV1 – current predicted FEV1) + (0.15 × baseline absolute FEV1). *denotes statistically significant difference (p<0.05).
Abbreviations: AV, absolute value; BD, bronchodilator; ICS, inhaled corticosteroids; SA/LA BA/MA, short acting/long acting β2 receptor agonist/muscarinic antagonist’.